Modification of DCs, following stimulation and appropriate antigen presentation, maintains an immunosupportive TME [18, 42], and TFDC-based immunotherapy could provide a clinical benefit to immunologically naïve tumors because of the preferable immunological balance in HLA-A low-expression GBM. This evidence concerns the gene HLA-A and glioblastoma.